Juvaris Adds Strategic to Series B Round
Juvaris BioTherapeutics Inc., a Pleasanton, Calif.-based developer of vaccines for cancer and infectious diseases, has held a second close on a previously-disclosed Series B round that could total $25 million. An undisclosed corporate investor was joined by existing backers SV Life Sciences and Kleiner Perkins Caufield & Byers.
27 January 2010•3 mins read
